NBRVF — Nabriva Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
U.S. STOCKS ON THE MOVE-Larimar Therapeutics, GSX Techedu, Riot Blockchain
Nabriva Therapeutics: Surges as pneumonia drug meets main goal in China study
Brief: Sinovant Sciences And Nabriva Therapeutics Announce Positive Topline Results From Phase 3 Trial Of Lefamulin In Chinese Adults With Community Acquired Bacterial Pneumonia (Cabp)
Nabriva Therapeutics PLC reports results for the quarter ended in March - Earnings Summary
Entered Into Open Market Sale Agreement With Jefferies On May 6 Relating To Sale Of Ordinary Shares
Brief: Nabriva Therapeutics Reports First Quarter 2021 Financial Results
Nabriva Therapeutics PLC expected to post a loss of 67 cents a share - Earnings Preview
Brief: Nabriva Therapeutics PLC Says Begun Exclusive Distribution Of Sivextro (Tedizolid Phosphate) In U.S.
Brief: Nabriva Therapeutics Posts Qtrly Loss Per Share $1.11
Brief: Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Brief: Nabriva Expects To Report $5.0 Mln Of Total Rev For Year Ended Dec 31, 2020
Brief: Nabriva Therapeutics Appoints Daniel Dolan As Chief Financial Officer
Brief: Study Demonstrates Macrolide-Resistance In S. Pneumoniae In The United States Exceeds 25 Percent Threshold Set In Current Community-Acquired Bacterial Pneumonia (Cabp) Treatment Guidelines
Brief: Nabriva Therapeutics Announces Retirement Of Its Chief Financial Officer
U.S. STOCKS ON THE MOVE-Sonoma Pharma, Walt Disney, NantHealth, Sellas Life Sciences
U.S. STOCKS ON THE MOVE-Pfizer, Disney, Tesla, Fat Brands
U.S. STOCKS ON THE MOVE-Nabriva Therapeutics, GigCapital3, Fat Brands, Niocan
Nabriva Therapeutics: Falls on pricing 6 mln share offering
Brief: Nabriva Therapeutics Announces Pricing Of $15 Million Public Offering